52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
J&J, On Covid-19 Says Like Many Organizations, We Are Evaluating Potential Benefit Of A Human Challenge Trials
Janssen Shows Findings From Global, Multi-Center Trial Examining Amivantamab In Combination With Lazertinib In Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Johnson & Johnson Says XWPharma Completes $40 Mln Financing and Appoints Leonard Blum as CEO
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Biotechnology & Drugs
1 Johnson And Johnson Plz
NEW BRUNSWICK, NJ
Chairman of the Board, Chief Executive Officer
Paulus A. Stoffels
Vice Chairman- Executive Committee, Chief Scientific Officer
Joaquin Boix Duato
Vice Chairman - Executive Committee
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Johnson & Johnson <JNJ.N> on Wednesday began a 60,000-person trial of an experimental single-shot COVID-19 vaccine that, if proven effective, could simplify distribution of millions of doses compared with leading rivals requiring two doses.
Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot COVID-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses.
Shares in Danish biotech firm Genmab <GMAB.CO> fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson <JNJ.N> over royalty payments for its key cancer drug.
(Adds ReiThera; updates Sanofi, AstraZeneca, Novavax, Johnson & Johnson) Sept 21 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines. The European Union also signed its...
U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.
New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients.
New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.
Some volunteers have quit Johnson & Johnson's COVID-19 vaccine trial in Spain after news of side effects in a participant in AstraZeneca's trial, the Spanish programme's lead investigator told Reuters on Tuesday.
News of serious side effects in one participant of AstraZeneca's COVID-19 vaccine trial led some volunteers in Johnson & Johnson's vaccine trial in Spain to drop out, its lead investigator told Reuters on Tuesday.
Johnson & Johnson's <JNJ.N> Janssen unit will begin mid-stage trials of its COVID-19 vaccine in Spain on Monday, the programme's lead investigator said.
Johnson & Johnson <JNJ.N> will seek 20,000 volunteers for late-stage human trials of its experimental coronavirus vaccine in hard-hit Latin America, one-third of the planned global total, one of its public health chiefs in the region said.
Johnson & Johnson <JNJ.N> said on Thursday its experimental coronavirus vaccine prevented hamsters from getting severely ill, as the drugmaker seeks to begin large, late-stage studies in humans later this month.
Canada reached an agreement in principle on Monday with both Novavax Inc <NVAX.O> and Johnson & Johnson <JNJ.N> for millions of doses of their experimental coronavirus vaccines, Prime Minister Justin Trudeau said.
Canadian Prime Minister Justin Trudeau says:
As the race to develop a safe and effective coronavirus vaccine reaches its final stages, pharmaceutical companies have started conducting large human trials in different countries. Some countries also have signed supply deals with the companies. Below is a summary of clinical...
Johnson & Johnson's <JNJ.N> Janssen unit will begin mid-stage trials for its coronavirus vaccine in Spain, the Netherlands and Germany next week, Spain's health minister said on Friday, as the U.S. drugmaker expands testing for its experimental shot.
Johnson & Johnson's Janssen unit will begin Phase II trials for its COVID-19 vaccine in Spain, the Netherlands and Germany next week, Spanish health minister Salvador Illa announced on Friday, as the U.S. drugmaker expands testing for its experimental shot.
U.S. pharmaceutical company Johnson & Johnson has added Chile, Argentina and Peru to the Latin nations where it plans to conduct Phase III trials for its vaccine against COVID-19, the company confirmed on Wednesday.
U.S. pharmaceutical company Johnson & Johnson has added Chile and Peru to the Latin nations where it plans to conduct Phase III trials for its vaccine against COVID-19, a university researcher said on Wednesday.
The U.S. Food and Drug Administration on Wednesday removed a boxed warning about increased risk of leg and foot amputations with Johnson & Johnson's diabetes drug Invokana.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.